Pharming (PHARM.AS) traded up 7.27 % during a 24 hours period ending at 07:35 PM Central Europe on Monday 26th. One Pharming stock can currently be bought for about EUR 1.05 on popular exchanges. Current supply of Pharming stocks is 707.8 mn. Pharming has a current market capitalization of EUR 716.3 mn and approximately EUR 18.7 mn worth of Pharming was traded on exchanges in the last 24 hours. Since last month end, Pharming has traded 10.89 % up. Simple moving average of last 200 days is at EUR 1.19. The highest price of past 52 weeks was recorded at EUR 1.82 on 01/28/2026. 52 weeks low was at EUR 0.82 on 10/19/2026.

Summary of the latest news for Pharming

Pharming Group NV is scheduled to present its latest quarterly results at a finance conference on 27 October 2026. Analysts expect earnings per share to rise modestly from the previous year, while revenue for the quarter is projected to increase compared with the corresponding period last year. For the current fiscal year, expectations point to a small rise in earnings per share relative to the prior year, and revenue forecasts for the year are also anticipated to grow above last year’s level. The company’s management will provide further detail during the conference.

Here is how related stocks have performed in the past 24 hours:

  • Sligro Food (SLIGR.AS) traded flat 0 % and now trades at EUR 9.08. Current market capitalisation for Sligro Food is EUR 400.1 mn. Sligro Food has a current price to earnings ratio of 10.72.

  • Amg Critical Materials Nv (AMG.AS) traded down -0.52 % and now trades at EUR 23.04. Current market capitalisation for Amg Critical Materials Nv is EUR 829.1 mn. Current price/earnings ratio for Amg Critical Materials Nv is 154.66.

  • Tomtom (TOM2.AS) traded down -3.01 % and now trades at EUR 3.7. Tomtom has a market capitalisation of EUR 454.9 mn. Tomtom has a current price to earnings ratio of 15.42.

  • Fugro (FUR.AS) traded up 4.08 % and now trades at EUR 7.66. Current market capitalisation for Fugro is EUR 852.8 mn.

About Pharming

Pharming Group NV is a specialty pharmaceutical company based in Leiden, Netherlands, that develops and produces human therapeutic proteins to address rare diseases and unmet medical needs. The company’s lead product, Ruconest, is a recombinant human C1 esterase inhibitor used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. Additionally, Pharming Group NV is involved in the development of recombinant human C1 inhibitor for treating HAE attacks and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has strategic collaborations with the Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on its Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of haemophilia A.